Associations between smoking, arterial pressure and serum cholesterol concentrations and IHD were identified initially by observation in the general population. Cigarette smokers were observed to be at higher risk of IHD than those who chose not to smoke. Those with higher arterial pressure and serum cholesterol concentrations had a greater risk of IHD compared with those with lower values. Such observations may describe a causal relationship; alternatively, these factors may be confounders for the real cause of disease. For example, smoking may be associated closely with both the actual cause, say factor X, and the disease itself. In the absence of an experiment one can only judge if such relationships are causal or coincidental, and such judgements are necessary, as experimenting on the healthy population is unethical. Randomly assigning children in their teenage years to smoking and non-smoking groups, forcing the former to smoke cigarettes heavily for many years and prohibiting the latter from doing so, could answer a number of important scientific questions on whether or not smoking causes IHD, lung cancer, chronic airways disease and so on, but such an experiment could not, and rightly so, ever be undertaken. However, it is both ethical and practical to test the antithesis of such relationships; namely, if elimination of cigarette smoking and reduction of arterial pressure and serum cholesterol concentrations are associated with a corresponding reduction in the incidence of IHD.
First, evidence from observational studies of smoking, arterial pressure and serum cholesterol concentration will be described in relation to IHD. Then the evidence will be reviewed from unifactorial experiments undertaken to reduce these risk factors and the frequency of IHD.
Observational Evidence from Individuals
A prospective survey of individuals is necessary to measure the relationship between any biological factor and a disease. Such a study is based usually on a representative sample of a populationideally, although it is never achieved in practice, a true random sample of the general population. Response rate to the initial screening survey should be as high as possible in order to avoid bias through non-response. Measurements are made with both accuracy and precision. Follow-up of all individuals over time is as complete as possible, with all cases of disease documented in a systematic and unbiased manner. Data from such a prospective survey are used to examine relations between biological factors measured at baseline, and subsequent risk of disease. There have been many such population studies of risk factors in relation to ischaemic heart disease, and one recent example from this country is the British Regional Heart Study.
This study [8] has reported on the relationship between smoking, arterial pressure, serum cholesterol concentrations and IHD, and was the first to do so for a representative sample of British men. In this prospective epidemiological survey, 7735 men aged 40-59 yr, drawn at random from the age and sex registers of general practitioners in 24 British towns were studied. From those selected for interview and examination, there was a 78 % response rate. A questionnaire was administered to provide demographic information, smoking habit, past medical history and so on, and the following measurements were made by a team of Research Nurses: arterial pressure, body mass index (weight/height 2 ), serum lipid concentrations etc. All men were followed up and all cases of sudden death or acute myocardial infarction recorded. After a follow-up period of 4.2 yr, 202 cases had occurred in this population as a result of IHD. Relationships between several biological characteristics and the subsequent risk of IHD were examined; the results for smoking, arterial pressure and serum cholesterol are summarized below.
Smoking
Current cigarette smokers exhibited approximately three times the risk of IHD compared with those who had never smoked. Relative risk was calculated by taking a ratio of the probabilities, or odds, of IHD amongst cigarette smokers compared with those who never smoked. If no relationship existed between smoking and IHD the ratio would be unity. As the ratio increases the relationship is more likely to be causal than coincidental. In this study the ratio was 3, which implies that the risk of IHD amongst smokers is greater than those who never smoked, not just by 3%, or 30%, but by 300%.
After adjustment for the effect of other IHD risk factors, pre-existing ischaemic heart disease, and age, the relationship between smoking and IHD in this study remained virtually unchanged. A similar relationship between smoking and IHD has been shown in other population studies [6] .
Arterial pressure
Both diastolic and systolic arterial pressures were related positively to risk of IHD. Unlike smoking habit, arterial pressure is distributed continuously, and to calculate IHD risk in the British Regional Heart Study men were ranked in order of magnitude of measurement, and then allocated into five groups of approximately equal size. The number of cases of IHD occurring in each quintile was used to calculate the probability of there being a case in each group. These odds were then expressed relative to men in the bottom quintile. For diastolic pressure, men in the top quintile of the distribution (diastolic pressure J; 90 mm Hg) had an estimated three-fold increase in risk of IHD relative to the bottom fifth (^ 72 mm Hg), while the remainder (72-90 mm Hg) were at intermediate risk.
For systolic pressure, there was an estimated two-fold increase in risk for the top 40 % of men (systolic pressure ^148 mm Hg) but there was no evidence of any trend at lower values.
Systolic and diastolic arterial pressure are so strongly associated it would be inappropriate to adjust one for the other when taking into account the effect of other variables. After adjustment for other IHD risk factors (except systolic pressure), and previous IHD, as well as age, the relationship between diastolic arterial pressure and IHD was largely unaltered. Similarly, the relationship between systolic pressure (without adjustment for diastolic pressure) and IHD was not altered significantly after adjustment for other risk factors.
A similar relationship for arterial pressure and IHD has been shown in other population studies [6] and, in common with smoking habit, it is judged to be causal.
Serum cholesterol
Total serum cholesterol concentration is related positively to risk of IHD and the British Regional Heart Study showed a continuous and marked trend of increased risk as the total concentration of cholesterol increased. Men in the top fifth of ranking for cholesterol (cholesterol ^ 6.5 mmol litre" 1 ) had three time the risk of IHD compared with men in the bottom fifth, and men within the middle range of total cholesterol (6-6.4 mmol litre" 1 ) had almost double the risk of men in the bottom fifth.
After adjustment for the effect of other IHD risk factors, pre-existing IHD and age, the association of cholesterol with IHD remained highly significant.
A similar relationship between cholesterol and IHD has been shown in other population studies [6] and, in common with smoking habit and arterial pressure, the relationship between serum cholesterol concentration and IHD is judged to be causal.
Limitations of observational evidence
The independent associations between smoking, arterial pressure, and serum cholesterol concentration and IHD may be causal, or these factors may be confounders for the real cause of the disease. To judge such relationships-whether they are causal or merely coincidental-several criteria are used. These include the strength of association; consistency; if the association displays a biological gradient; specificity and the temporal relationship. Of all these, strength of association is probably the most important.
Relative risk measures strength of an association, namely the rate of disease in those exposed to a factor relative to the rate in those not exposed. For example, mortality rate from lung cancer in cigarette smokers is approximately 10 times the rate in non-smokers, a relative risk of 10-fold. To explain excess lung cancer among smokers by any factor other than smoking requires a factor so closely related to both smoking and disease that it should be detected easily. As no such factor has been identified, smoking is considered to be the principal cause of lung cancer. The larger the relative risk the more likely it is that the association is causal.
Consistency of an association implies that the same association has been observed in different populations, different places and at different times by different scientists using different methods, but with the same results. When the evidence for an association is consistent, such an association is more likely to be causal. A biological gradient; or dose-response curve between the degree of exposure and risk of disease implies that the association is more likely to be causal. Specificity of an association may apply to exposure or disease, or both, and the more specific a relationship the more likely it is causal. Finally, exposure must precede disease if the relationship is causal. Other criteria include biological plausibility of the association, coherence of all scientific evidence, and reasoning by analogy.
Applying these criteria to the associations observed between smoking, arterial pressure, serum cholesterol concentration and IHD, each is judged to be causal.
Experimental Evidence from Individuals
If smoking, arterial pressure and serum cholesterol concentration are considered to be related causally to IHD, what experimental evidence is there that elimination, or reduction of, such factors will reduce the frequency of disease? Unifactorial experiments have been conducted in relation to smoking, arterial pressure and serum cholesterol concentration and the results are reviewed below.
Smoking
Only one randomized controlled trial of antismoking advice in relation to mortality from IHD and other causes of death has been reported, and this was commenced in 1968 as part of the Whitehall Study [7] .
Between 1968 and 1970, 16016 men aged 40-59 yr were screened during the Whitehall Study of London civil servants. Cigarette smokers (n = 1445) with the highest risk of IHD or chronic bronchitis, or both, based on a multivariate combination of risk factors were selected, and allocated randomly to two groups. In the intervention group, 744 men were recalled for individual advice. A large majority declared a wish to stop smoking and were supported to do so. No other advice was given except on calorie restriction for those who gained weight. The remaining 731 men served as a usual care group and were not recalled to receive specific advice on smoking, although a minority may have been advised not to do so by their general practitioner. The baseline characteristics of the two groups were comparable.
A dramatic reduction in reported consumption of cigarettes occurred in the intervention group; after a year it was 25 % of that of the usual care group. Thereafter, it tended to increase a little, whereas consumption in the usual care group declined slowly. The proportion of responders at the 1-, 3-and 9-yr follow-up survey who stated they were not smoking any cigarettes was 63%, 57% and 55%, respectively. Over 10 years there were 251 deaths (table I) and the majority of these were attributed to IHD. No significant difference emerged between intervention and usual care in numbers of deaths from IHD, or any other specific cause; and there was no difference in all causes of mortality. The largest difference was seen for all cancer deaths, other than lung cancer, which were nearly 40 % higher in the intervention compared with the usual care group, but this difference may have been produced by chance.
Therefore, although observational data strongly relate smoking to IHD, evidence from the only randomized control trial of anti-smoking advice showed no significant effect on death from IHD. Interestingly, the 18% reduction in IHD deaths (95% confidence intervals of -43% to +18%) seen in the intervention group is consistent with that observed in the British Doctors' Study, in which comparison was made between those who chose to stop smoking and those who continued to smoke cigarettes.
Arterial pressure
Three randomized placebo control trials of reduction in arterial pressure have been reported: the Veterans Administration Co-operative Study Group, Australian National Blood Pressure Study, and the MRC Trial of Mild Hypertension. The Hypertension Detection and Follow-up Programme is not considered here, because it was a trial of hypertension management rather than a placebo control study.
Veterans Administration Co-operative Study Group [9, 10] . In 1963 this group was formed to assess, by clinical trial, drug treatment of essential hypertension (excluding malignant hypertension) in relation to morbidity and mortality [9, 10] . A randomized double-blind placebo control trial was started in April 1964 to compare hydrochlorthiazide plus reserpine plus hydrallazine against placebo in male hypertensive patients with diastolic arterial pressures averaging between 90 and 129 mm Hg. Patients were randomized within pre-defined strata of diastolic pressure.
By 1967 the first report on 143 male hypertensive patients with severe diastolic hypertension, averaging between 115 and 129mmHg was published [9] . Twenty-two terminating events, mainly the development of retinal haemorrhages, exudates or papilloedema, but also dissection and rupture of aortic aneurysms, stroke and progressive renal failure occurred, one in those actively treated and the remaining 21 in the placebo group. Ischaemic heart disease was not a terminating event, but in this small group of patients three cardiac events occurred, all in the placebo group: two non-fatal myocardial infarctions and one sudden death without autopsy (table II) .
Those 380 male patients with diastolic pressures between 90 and 114 mm Hg were reported in 1970 [10] . Again, there were fewer terminating events in the treatment group, approximately 25 % of those in the placebo group, and these included deaths, other cardiovascular events such as cardiac failure and treatment failures, but not IHD. The latter was not a terminating event, but 24 such cases occurred: 11 in those treated actively and 13 in the placebo group, a difference which was not statistically significant (table II) . As expected, within the range 90-114 mm Hg incidence of morbid events was lower in those with prerandomization arterial pressure 90-104 mm Hg, and the beneficial effect of treatment was less than half that seen for those with diastolic pressure 105-114 mm Hg. The case for reducing arterial pressure to decrease the risk of IHD was not demonstrated by this study.
Australian Therapeutic Trial in Mild Hypertension [1] . A clinical trial of anti-hypertensive drug treatment on 3427 men and women aged 30-69 yr was commenced in Australia in 1973, denning mild hypertension as a diastolic pressure of 95 mm Hg or greater and less than 110 mm Hg, with a systolic pressure less than 200 mm Hg after two screening examinations [1] .
Subjects were randomly assigned (with stratification for age and sex) to active treatment with chlorothiazide, and/or as second line drugs methyldopa, propranolol or pindolol, and as third line drugs hydrallazine or clonidine, all against matching placebo. Only 2218 subjects (64.7%) continued their trial regimen, either until a trial end-point occurred, or until the end of the study. The regimens were prematurely stopped by 1209, nearly 50 % of their own volition, rather than on medical advice. Follow-up was for 4 years on average, and complete in the majority of patients.
IHD was the most frequently occurring trial end-point in both groups (table II) and the total number of IHD events was similar, as was the number of fatal events, non-fatal myocardial infarction and other manifestations of IHD (symptoms of angina, and the occurrence of ECG changes denned as ischaemia but not fulfilling WHO criteria of myocardial infarction). In common with the previous study, there was no evidence that reducing arterial pressure reduced the risk of IHD. [5] . From 1977, 17354 patients with mild hypertension (diastolic 90-109 mm Hg) were recruited to this controlled trial of drug treatment, and this represented approximately 3% of those invited and screened [5] . Patients were allocated randomly at entry to one of four treatments: the thiazide diuretic bendrofluazide; placebo tablet similar in appearance to bendrofluazide; the beta blocker propranolol; and placebo tablet similar in appearance to propranolol. Stratification within blocks of eight within each sex, 10-year age group and clinic was part of the randomization procedure.
MRC Trial of Treatment of Mild Hypertension
The therapeutic objective for those randomized to active treatment was to reduce diastolic pressure (phase V) to less than 90 mm Hg within 6 months of entry to the study. Compliance with treatment varied by sex, being better in women, and the cumulative percentage of people not taking either active drug by 5.5 yr was approximately 30%, which included both those who withdrew from their randomly allocated regimen, but continued on follow-up, and those lapsing from the trial.
In terms of control of arterial pressure, annual measurement showed the proportion of patients with diastolic pressure less than 90 mm Hg was consistently greater in the thiazide group compared with the beta-blocker group, and in both groups it was always greater than 60%, ranging from 60 % to 79 %. For the control group between one-third and one-half of those taking placebo had a diastolic pressure less than 90 mm Hg, although different subjects constituted this total at each annual review. Only 18% of the placebo group, for whom arterial pressure measurement at the first three annual visits was recorded, had diastolic arterial pressures less than 90 mm Hg on each of these three occasions. Approximately 22 % of those randomized to placebo developed diastolic arterial pressures above the mild range, compared with only 1.7% of those receiving active treatment.
Coronary events were the most commonly reported end-point in this study (table II) and there was no difference between active treatment (taking bendrofluazide and propranolol together) and placebo in the total number of coronary events, or separately, the number of fatal and nonfatal coronary events. All-cause mortality was almost identical in the two groups. For coronary events, and for all-cause mortality, there were no statistically significant differences between the treatment effects of bendrofluazide or propranolol when examined separately.
In summary, none of the placebo control trials of reduction in arterial pressure has shown any benefit in terms of reducing the incidence of IHD, although all have reported a significant reduction in the frequency of stroke.
Cholesterol
Three primary prevention trials of reduction of serum cholesterol concentrations have been reported, all using a combination of diet and drug therapy: the WHO Co-operative Study, Lipid Research Clinics Coronary Primary Prevention Trial and the Helsinki Heart Study.
WHO Co-Operative Study [2] . This randomized double-blind controlled trial was commenced in 1965 to test the hypothesis that the incidence of IHD in middle-aged men could be reduced by decreasing their increased serum cholesterol concentration [2] .
The study was carried out in three European centres-Edinburgh, Budapest and Prague. Serum cholesterol was measured in 15745 healthy male volunteers aged 30-59 yr, of whom 26259 were invited to participate. Subsequently, 15745 were assigned to three groups: 5331 men in the upper one-third of the cholesterol distribution were assigned at random to take ethyl chlorophenoxyisobutyrate (clofibrate); the other 50% of the upper one-third, numbering 5296, constituted a randomized control group taking identical capsules containing olive oil. A second control group of similar size, 5118, chosen at random from the lowest one-third of cholesterol distribution, also received olive oil capsules.
Men were recruited in different ways: from lists of blood donors, electoral rolls, tuberculosis survey registers and by advertising amongst the general public. Recruitment started in 1964 and was completed by March 1972, and the trial was completed by the late summer of 1976. The lifestyle of participants was not influenced intentionally, and there was no planned intervention in relation to other risk factors for IHD. The high serum cholesterol groups were almost identical in baseline characteristics.
Of the 5331 in the clofibrate group, 3586 completed 5 years of the trial, 1246 failed to continue for reasons other than medical, and those leaving the trial in the other two groups were of similar number.
There was a reduction of approximately 9 % in serum cholesterol concentration (ranging from 7 % to 11 % in the three centres) over the course of the trial. This was associated with a 20% reduction in the incidence of all major IHD events (table III) in the treatment group compared with the high cholesterol control group; this reduction was confined to non-fatal myocardial infarctions, which were reduced by 25%. The incidence of fatal IHD was similar in the two high cholesterol groups, and there was no significant difference in the incidence of angina. The number of deaths from all causes in the clofibratetreated group significantly exceeded those in the high cholesterol control group. [4] . This double-blind placebo control trial tested the efficacy of reducing serum cholesterol concentration in the primary prevention of IHD.
Lipid Research Clinics Coronary Primary Prevention Trial
Between July 1973 and July 1976, 480000 men aged 35-59 yr were screened, of whom 3810 healthy men were entered into the trial with a serum cholesterol of 6.8 mmol litre" 1 or greater (the 95th percentile for men aged 40-49 yr) and with an LDL cholesterol concentration of 4.9 mmol litre" 1 or greater, despite treatment with diet. Men with triglyceride concentrations averaging greater than 3.4 mmol litre" 1 , or with Type III hyperlipoproteinaemia, were excluded; four men entered into the trial and found subsequently to have the latter disorder were removed from the study, two from each of the treatment groups.
Randomization was by the permuted block method, to two treatment groups within eight prognostic strata at each of 12 clinics. Baseline characteristics were essentially the same in the two groups. Subjects were prescribed either the bile acid sequestrant cholestyramine resin or an equivalent amount of placebo. Follow-up was for a minimum of 7 years and vital statistics for all men who originally entered the study were known. Compliance with treatment was similar in the two groups.
Average reductions in total serum cholesterol concentration and LDL cholesterol in the cholestyramine group were 13.4% and 20.3%, respectively, which were 8.5% and 12.6% greater than those observed in the placebo group. There was an increase in HDL cholesterol, and a larger increase in triglyceride concentration attributable to cholestyramine therapy.
The incidence of definite IHD deaths, definite non-fatal myocardial infarction, or both, was 19% lower in the cholestyramine group, and this difference was statistically significant (table III) . The reduction was seen for both fatal and nonfatal manifestations of IHD. There was no significant difference in all-cause deaths between the two treatment groups.
Helsinki Heart Study [3] . This randomized placebo control study of 4081 middle-aged men (40-55 yr) with hyperlipidaemia was designed to investigate the effect of gemfibrozil, a fibric acid derivative, on the incidence of IHD.
Patients were selected from 23531 men employed by the Finnish Posts and Telecommunications Agency, the Finnish State Railways and five industrial companies in Finland. Of 18966 (80.6%) who agreed to participate in the screening, 4081 healthy men met the entry criteria and were willing to participate. All had non-HDL cholesterol (total cholesterol minus HDL cholesterol) concentrations ^5.2 mmol litre" 1 on two successive measurements. Triglycerides were not measured in the initial screen. Random assignment to receive either gemfibrozil or placebo followed, and the two treatment groups did not differ in their baseline characteristics.
Of the 4081 randomized initially, 2859 (70.1 %) continued in the trial until its completion, and the dropout rates in the gemfibrozil and placebo groups were comparable over time. Compliance judged by capsule counts was similar in the two groups. All subjects were followed for 5 years and included in the analysis; none was lost to followup.
In the gemfibrozil group, total serum cholesterol concentration initially decreased by 11%, LDL cholesterol by 10%, that of non-HDL cholesterol by 14%, and that of triglyceride by 43%; HDL cholesterol increased rapidly, by more than 10%. These changes were followed by consistent serum concentrations of total and of LDL cholesterol, and a small increase in triglyceride concentration, during the last years of the trial. The placebo group showed only minimal and random fluctuations from the baseline values.
The overall reduction in frequency of cardiac end-points in the gemfibrozil group was 34% (95% confidence intervals 8.2-52.6%) and this difference was explained almost entirely by a lower frequency of non-fatal myocardial infarction (table III) . There was no statistically significant difference in the total number of deaths in the two groups and no significant differences between the groups in any specific non-cardiovascular causes of death.
Limitations of experimental evidence
A unifactorial experiment which reduces exposure to a risk factor and shows a corresponding reduction in the incidence of IHD is powerful evidence in support of the original association being causal. However, experiments to reduce risk of IHD also have their limitations. Elimination of, or reduction in exposure to, a biological factor does not necessarily reverse risk of disease in those who have already been exposed, and therefore a negative trial result does not negate evidence for causality from observational studies. In addition, the extent to which a risk factor is reduced may be too small to influence subsequent risk of disease. Risk factor reduction may be for too short a period, and follow-up in experimental trials may be too short to detect any benefit that may only be evident in the long term. In addition the alteration of risk factors may be too late in the natural history of the disease. Partial control of one risk factor in a multifactorial disease may be mitigated by the continuing presence of other risk factors. A negative trial may also, of course, be because the original association between a biological factor and disease was coincidental rather than causal. From the unifactorial clinical trials of cessation of smoking, reduction in arterial pressure and in serum cholesterol concentration, it is clear that experimental evidence for the relationship between cholesterol and IHD is strong, but not so for smoking and arterial pressure.
SUMMARY
There is evidence from population studies of strong positive associations between smoking, arterial pressure and serum cholesterol concentration and risk of ischaemic heart disease, and these appear to be independent of one another, but the evidence from unifactorial trials of risk factor reduction is less impressive.
For smoking, there is no good experimental evidence that cessation reduces the risk of IHD, but there are good observational data to show that those who choose to cease have a lower mortality from IHD, and all causes of death, compared with those who continue to smoke. For arterial pressure, none of the randomized controlled trials has shown any benefit from a reduction in arterial pressure in relation to IHD, although the same studies have shown that risk of stroke is reduced substantially.
The best trial evidence for risk factor reduction is seen for serum cholesterol, and in all three major placebo control trials, reduction was associated with a corresponding decrease in the incidence of IHD; for each 1% decrease in serum cholesterol concentration there was a 3 % reduction in risk of IHD. However, total mortality was unchanged, and in the case of the WHO CoOperative Study there was a statistically significant excess of deaths in the treatment group. The use of drugs in the primary prevention of IHD is a matter of judgement based on the risk of disease, the efficacy of the treatment and side effects.
